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We demonstrated previously that p53 mutations can
be detected in ultraviolet B-irradiated mouse skin
months before the gross appearance of skin tumors
and that applying sun protection factor 15 sunscreens to
mouse skin before each Kodacel-filtered FS40 sunlamp
irradiation resulted in the reduction of such mutations.
To determine whether there is an association between
reduction of ultraviolet-induced p53 mutations by
sunscreens and protection against skin cancer using
an environmentally relevant light source, we applied
sunscreens (sun protection factors 15–22) on to the
shaved dorsal skin of C3H mice 30 min before each
exposure to 4.54 kJ ultraviolet B (290–400 nm) radia-
tion per m2 from a solar simulator. Control mice
were treated 5 d per wk with ultraviolet only or
vehicle plus ultraviolet. p53 mutation analysis indi-
cated that mice exposed to ultraviolet only or
vehicle plus ultraviolet for 16 wk (cumulative exposure
to 359 kJ ultraviolet B per m2) developed p53 mutations
Excessive exposure to sunlight causes damage to the skinincluding erythema, edema, hyperplasia, formation ofsunburn cells, photoaging, suppression of the immunesystem and skin cancer (Urbach, 1969; Parrish et al,1982; Kligman and Kligman, 1986; Gilchrest, 1990;
Young, 1990; Kripke, 1991). In order to protect against some of
the harmful effects of sunlight, most lightly pigmented individuals
are advised to use sunscreens with a sun protection factor (SPF) of
15 or greater. Although commercial sunscreens were originally
developed to protect against sunburn, laboratory studies have shown
that some sunscreens are also quite efficient in protecting against
ultraviolet (UV)-induced DNA damage (Freeman et al, 1988; van
Praag et al, 1993; Ley and Fourtanier, 1997; Bykov et al, 1998),
induction of p53 and p21 proteins (Ponten et al, 1995; El-Deiry
et al, 1995), skin aging (Kligman et al, 1982; Young, 1990;
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at a frequency of 56%–69%, respectively, but less than
5% of mice treated with sunscreens plus ultraviolet
showed evidence of p53 mutations. More importantly,
100% of mice that received a cumulative dose of 1000 kJ
ultraviolet B per m2 only, or vehicle plus ultraviolet B
developed skin tumors, whereas, the probability of
tumor development in all the mice treated with the
sunscreens plus 1000 kJ ultraviolet B per m2 was
2% and mice treated with sunscreens plus 1500 kJ
ultraviolet B per m2 was 15%. These results demon-
strate that the sunscreens used in this study not only
protect mice against ultraviolet-induced p53 muta-
tions, but also against skin cancers induced with solar-
simulated ultraviolet. Because of this association, we
conclude that inhibition of p53 mutations is a useful
early biologic endpoint of photoprotection against an
important initiating event in ultraviolet carcino-
genesis. Key words: mutation protection/photocarcino-
genesis/sun protection factor/tumor suppression. J Invest
Dermatol 112:763–768, 1999
Fourtanier et al, 1992), sunburn cell formation (Wolf et al, 1995),
immunosuppression (reviewed in Gasparro et al, 1998; Ullrich et al,
1999), and development of skin cancer (Kligman et al, 1980; Wulf
et al, 1982; Forbes et al, 1989; Flindt-Hansen et al, 1990; Fourtanier,
1996). In addition, a few studies have shown that sunscreens can
prevent the emergence of actinic keratoses in humans (Thompson
et al, 1993; Naylor et al, 1995) and help reduce skin cancer risk in XP
patients (Kondoh et al, 1994). Moreover, epidemiologic evidence
suggests that comprehensive use of sunscreens may reduce the risk
of skin cancer by 80% (Stern et al, 1986).
The relative effectiveness of sunscreens is currently evaluated on
the basis of their ability to prevent erythema caused by exposure
of human skin to UV radiation. As the relationship between
erythema and skin cancer is unknown, it is important to develop
other earlier end-points that might be more accurate predictors of
the effectiveness of sunscreens in preventing skin cancer than
erythema. In this regard, mutation of the p53 tumor suppressor
gene may serve as a short-term molecular surrogate for the long-
term biologic end-point of skin cancer development because
mutations in this gene have been shown to be a key component
of the disease pathway, rather than merely a correlative marker.
Several studies have shown that a high percentage of sunlight-
induced human skin cancers (reviewed in Brash et al, 1996 and
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Nataraj et al, 1995) and UV-induced murine skin cancers (Kress
et al, 1992; Kanjilal et al, 1993; Dumaz et al, 1997; Ananthaswamy
et al, 1998) contain unique p53 mutations (C→T and CC→TT
transitions) at dipyrimidine sites. In addition, unlike p53 mutations
in other types of cancer, the mutation of p53 by UV radiation
appears to be an early event in UV carcinogenesis (Ziegler et al,
1994; Kanjilal et al, 1995; Berg et al, 1996; Jonason et al, 1996;
Ren et al, 1996; Ananthaswamy et al, 1997), and it can serve as an
Figure 1. UV absorption spectra of the sunscreen formulations.
Monochromatic protection factor spectra of the four sunscreens (P531–
P534) and the vehicle (P530) were obtained by spectrophotometric
measurements of the formulations applied as a thin layer (1.5 mg per cm2)
on Transpore tape (Diffey and Robson, 1989). The composition of the
sunscreens and their human SPF are shown in Table I.
Table I. Sunscreen formulations used in this study
Composition (%)
Human Uvinula Parsola Eusolexa Mexoryla Parsola
Sunscreen SPF N539 (UVB) MCX (UVB) 232 (UVB) SX (UVA) 1789 (UVA)
P530 (vehicle)b 0 – – – – –
P531 16 10 0 2 0 0
P532 15 0 8 2 0 0
P533 15 9 0 0.3 0.7 3
P534 22 10 0 0.2 3.25 1.5
aUvinul N-539, octocrylene; Eusolex 232, phenylbenzimidazole sulfonic acid; Parsol MCX, Octyl methoxycinnamate; Parsol 1789, butyl methoxydibenzoylmethane;
Mexoryl SX, terephthalylidene dicamphor sulfonic acid.
bOil-in-water emulsion (10% silicone, 2% organic esters, and 15% polyol; mineral oil free).
Figure 2. Detection of p53 mutations at codons 154–155 in UVB-irradiated mouse skin by allele-specific polymerase chain reaction and
SCCP. DNA was isolated from mouse skin exposed to 359 kJ of solar-simulated UVB radiation per m2 (2752 kJ total UV radiation per m2), amplified
using mutant-specific primers and an aliquot of the PCR product was subjected to SSCP analysis. Data presented here reveal that the DNA from three
(B, lanes 2, 4, and 6) of eight UV-irradiated mouse skin and three (C, lanes 2, 5, and 8) of eight mouse skin treated with P530 (vehicle) plus UV gave
rise to amplified bands, indicating the presence of p53 mutations in these samples. In contrast, DNA from all eight unirradiated mouse skin did not
amplify (A, lanes 1–8), whereas DNA from a tumor known to contain mutations at codons 154–155 gave rise to highly amplified bands (lanes marked 1).
indicator of prior solar exposure in humans (Nakazawa et al, 1994;
Urano et al, 1995; Ouhtit et al, 1997, 1998).
In an attempt to develop other earlier end-points that might be
more accurate than erythema in predicting the effectiveness of
sunscreens in preventing skin cancer, we found that mutations in
p53 arose very early during UV skin carcinogenesis and that
application of SPF-15 sunscreens to mouse skin before each UV
irradiation protected mice against development of such mutations
(Ananthaswamy et al, 1997). Those results suggested that p53
mutations may serve as a short-term molecular surrogate for the
long-term biologic end-point of skin cancer development. Those
studies, however, were performed using a Kodacel-filtered FS40
sunlamp, which has a different UV spectrum than that present in
natural sunlight. Also, we did not test whether reduction of p53
mutations protected mice against skin cancer development. We
therefore investigated whether p53 mutations occur in mouse skin
exposed to solar-simulated UV radiation, whether this effect could
be reduced with sunscreen use, and whether there is an association
between reduction of UV-induced p53 mutations by sunscreens
and protection against skin cancer development in a mouse model.
MATERIALS AND METHODS
Mice Specific-pathogen-free female C3H/HeNCr(MTV-) mice (8–
12 wk old) were purchased from the NCI-Frederick Cancer Research
Facility Animal Production Area (Frederick, MD). The animals were
maintained in facilities approved by the Association for the Assessment and
Accreditation of Laboratory Animal Care International and in accordance
with current United States Department of Agriculture, Department of
Health and Human Services, and National Institutes of Health regulations
and standards. All animal procedures were reviewed and approved by the
Institutional Animal Care and Use Committee. The mice received NIH-
31 open formula mouse chow and sterile water ad libitum. Ambient light
was controlled to provide regular cycles of 12 h of light and 12 h of
darkness. The mice were 8–10 wk old at the start of each experiment.
Solar simulator An Oriel 1000 W solar UV simulator (Oriel Corpora-
tion, Stratford, CT), equipped with an atmospheric attenuation filter (WG
320; 1 mm thick), a visible-infrared filter (Schott UG 11; 1 mm thick)
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and a dichroic mirror to further reduce visible and infrared energy was
used to provide radiation with a close UVB/UVA spectral match to
sunlight. Model 81292, which produced a beam size of 152 3 152 mm
was used. The irradiance of the source, uniformity of the beam, and the
spectral power distribution was measured with a model 742 spectroradi-
ometer (Optronic Labs, Orlando, FL), equipped with a cosine corrected
Teflon dome diffuser, interfaced to a Compaq 386s personal computer.
This filtered xenon light source provided a simulated solar UVR spectrum
(290–400 nm) that was nearly devoid of visible and infrared radiation. The
total UV fluence of the solar simulator was 42.58 6 0.23 W per m2, with
5.55 6 0.16 W UVB (290–320 nm) per m2 and 37.03 6 0.08 W UVA
per m2 .
Irradiation of mice The dorsal hair of the mice was removed with
electric clippers, and the mice were placed in specially constructed Plexiglas
holders designed to fit exactly within the 152 3 152 mm area of the
beam, where variability of the irradiance did not exceed 6 5%. These
dividers were covered with a quartz lid, which reduced the incident UV
dose by µ10%. Groups of 16 mice were irradiated five times per week
(Monday through Friday) with 4.54 kJ UVB per m2 and 30.26 kJ UVA
per m2 for a total of 34.8 kJ UV radiation per m2 per exposure. Because
previous studies (Forbes et al, 1989; Kress et al, 1992; Kanjilal et al, 1993;
Ananthaswamy et al, 1997; Dumaz et al, 1997) demonstrated that induction
of p53 mutations as well as skin cancer in this model is a function of UVB
exposure, the data presented here are expressed as mutation frequency
and/or tumor probability vs. cumulative UVB dose. Control mice were
shaved but not exposed to UV or sunscreens. All mice were shaved once
per week.
Sunscreen application Two types of sunscreens were used in these
studies; UVB only absorbers (formulations P531 and P532) and UVB and
UVA absorbers (formulations P533 and P534). The composition of the
sunscreens used and their human SPFs are shown in Table I. The UV
absorption spectra of the sunscreens are shown in Fig 1. The vehicle
(formulation P530), an oil in water emulsion, was the same for all
preparations. All preparations were formulated by L’Oreal, Paris. The
sunscreens and the vehicle preparations were applied to the shaved dorsal
skin of C3H mice (100 µl per mouse; µ2 mg per cm2) with a 1 ml syringe
and spread by hand, and 30 min later, the mice were irradiated with the
solar simulator at a dose of 4.54 kJ UVB per m2 per exposure. The mice
were held in cages without bedding prior to irradiation. In the p53
mutation experiments, mice were chronically irradiated 6 sunscreen for
16 wk (cumulative UVB dose, 359 kJ per m2) because of our finding that
p53 mutations were detected at a relatively high frequency at this time
point in mouse skin exposed to Kodacel-filtered FS40 sunlamps or solar
simulator (Ananthaswamy et al, 1997; Ananthaswamy et al, unpublished).
In the carcinogenesis experiment, all mice in the UV only and
vehicle plus UV groups were irradiated until they developed at least one
tumor. Irradiation of mice in the sunscreen plus UV groups continued
until the mice developed at least one tumor, the animal died of natural
causes, or when the experiment was terminated (µ70 wk of irradiation).
The animals were examined weekly for tumor development.
Allele-specific polymerase chain reaction and single-strand con-
formation polymorphism (SSCP) In contrast to tumor tissues in
which mutant p53 alleles are expected to be present at very high frequencies,
Table II. Inhibition of UVB-induced p53 mutations in C3H mouse skin by sunscreens
No. of mice with mutations/no. mice treated
Codons
Treatmenta 148 154–155 175–176 Mutation frequency % inhibitionb pc
None 0/16 0/16 0/16 0/16 –
UV only 1/16d 3/16d 5/16 9/16 –
P530 (vehicle) plus UV 2/16e 3/16e 6/16e 11/16 – NS
P531 plus UV 0/16 0/16 0/16 0/16 100 0.006
P532 plus UV 0/16 1/16 0/16 1/16 90 0.02
P533 plus UV 0/16 1/16 1/16 2/16 80 0.05
P534 plus UV 0/16 0/16 0/16 0/16 100 0.006
aMice were exposed to 359 kJ UVB per m2 (2752 kJ total UV per m2) radiation with and without sunscreens, as described in Materials and Methods. Epidermal DNA was
analyzed for p53 mutations at codons 148, 154–155, and 175–176 by allele-specific polymerase chain reaction and SSCP.
bCompared with the average number of mutations found in UV only and vehicle plus UV groups.
cProbability values determined by use of the Fisher exact test comparing experimental groups with UV only control; NS 5 p . 0.05.
dOne mouse had mutations in both codons.
eOne mouse had mutations in all three codons.
the frequency of mutations in UV-irradiated skin is expected to be very
low because mutations are present in only a small fraction of the overall
cell population. Because of this problem, detection of p53 mutations in
UV-irradiated skin by conventional procedures is rather difficult. We
therefore developed sensitive techniques involving allele-specific poly-
merase chain reaction and SSCP to detect p53 mutations. In addition, we
targeted tandem CC→TT mutations at specific codons known to be
mutated in UV-induced mouse skin cancers. We found previously that
UV-induced mouse skin cancers contain tandem CC→TT mutations at
codons 148, 154–155 or 175–176 (Kanjilal et al, 1993; Ananthaswamy
et al, 1997). By using allele-specific primers for these codons, we amplified
genomic DNA from UV-irradiated mouse skin by PCR and the products
were subjected to SSCP analysis. In brief, for 25 µl reaction volumes,
mixtures containing 180 ng genomic DNA, 0.2 µM 59 primer, and 0.2 µM
39 primer were incubated in Gene Amp reaction buffer (Perkin-Elmer
Cetus, Norwalk, CT) at 94°C for 4 min. Subsequently, 75 µM of each of
the four dNTPs, 2.5 µCi of [α-32P]-dCTP and 0.75 U Taq polymerase
(Perkin-Elmer Cetus) were added, and the samples amplified by 25 cycles
of denaturation, annealing, and extension in a thermocycler (Perkin-Elmer
Cetus). SSCP analyses were performed using an MDE (mutation detection
enhancement) ultrahigh-resolution gel (FMC Bioproducts, Rockport, ME)
according to pre-established procedures that yield the highest sensitivity
(Ananthaswamy et al, 1997). In brief, 5 µl of the PCR product diluted
with 2 µl sequencing stop solution were heated at 94°C for 5 min, quick
cooled on ice, loaded on a 0.5 3 MDE gel, and resolved by electrophoresis
at 6 W. Autoradiography was performed on dried gels to visualize the bands.
RESULTS
Sunscreens inhibit p53 mutations in UV-irradiated mouse
skin Epidermal DNA from mouse skin exposed to UV 6
sunscreens for 16 wk (cumulative UVB dose, 359 kJ per m2) was
amplified using primers specific for detecting tandem CC→TT
mutations at codons 148, 154–155, or 175–176 (Ananthaswamy
et al, 1997). Representative SSCP data shown in Fig 2 indicate
that the primers specific for mutant p53 sequences at codons
154–155 amplified genomic DNA from the skin of three of eight
UV-irradiated mice (B, lanes 2, 4, and 6) and from three of eight
mouse skin treated with P530(vehicle) plus UV (C, lanes 2, 5, and
8). In contrast, the mutant-specific primers did not amplify DNA
from all eight unirradiated mouse skin (A, lanes 1–8). As expected,
DNA from a UV-induced mouse skin tumor known to contain
codons 154–155 mutation was highly amplified (lanes marked 1).
Pooled data for all three codons reveals the presence of nine p53
mutations in 16 mice exposed to UV only and 11 mutations in 16
mice treated with vehicle (P530) plus UV (Table II). In contrast,
none of 16 mice treated with sunscreen preparation P531 plus UV
or P534 plus UV had any p53 mutations, and only one of 16 mice
treated with P532 plus UV and two of 16 mice treated with
P533 plus UV had detectable p53 mutations. Overall, the sunscreens
used in this study inhibited the number of UVB-induced p53
mutations by 80%–100%.
Sunscreens protect mice against UV-induced skin
damage At termination of the p53 mutation experiments
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Figure 3. Protection against UV-induced skin damage by sunscreen
application. Damage to mouse skin was assessed after chronic exposure
of mice to 359 kJ solar-simulated UVB radiation per m2 (2752 kJ total
UV radiation per m2; µ16 wk of exposure) 6 sunscreen. Visible skin
damage along the mid-dorsum is clearly visible in mice exposed to UV
only and P530 (vehicle) plus UV, whereas no such damage is visible in
mice treated with any of the sunscreens plus UV. Dark patches on the skin
of some mice are caused by pigmentation that occurs during the hair
growth cycle.
described above, all mice were examined visually for UV-induced
skin damage. As shown in Fig 3, mice treated with UV only or
vehicle plus UV for 16 wk (cumulative UVB dose, 359 kJ per
m2) exhibited severe skin damage such as hyperpigmentation,
sunburning, and wrinkling along the mid-dorsum, whereas mice
treated with sunscreens plus UV had very little or no visible skin
damage and looked similar to that of unirradiated mouse skin.
Figure 4. Sunscreen application prevents UV-induced skin cancer
induction. Sunscreens were applied to the dorsal skin of mice 30 min
before each UV exposure. The probability of tumor development was
calculated for groups of mice exposed to: UV only (j); vehicle plus UV
(r); sunscreen P531 plus UV (s); sunscreen P532 plus UV (n); sunscreen
P533 plus UV (u); sunscreen P534 plus UV (e); and plotted versus the
cumulative dose of solar-simulated UVB radiation received by the mice.
Sunscreens protect against UV-induced skin cancers in
mice As the most relevant biologic end-point for the evaluation
of sunscreens is skin cancer, we performed a long-term UV
carcinogenesis study with and without sunscreens. The results of
this experiment (Fig 4), indicate that all mice exposed to UV only
or vehicle plus UV developed one or more skin tumors after a
cumulative exposure to µ1000 kJ UVB per m2 (48 wk of
irradiation), whereas none of the mice treated with sunscreens
P531, P532, or P534 plus 1000 kJ UVB per m2 developed skin
cancer and only one of 13 (8%) surviving mice treated with
sunscreen P533 plus UVB developed a skin tumor following
exposure to 1000 kJ UVB radiation per m2. Although additional
tumors did develop in sunscreen-treated mice upon continued
exposure to UV, the frequency of such tumors was very low. For
example, after 1500 kJ UVB irradiation per m2 (70 wk), only three
of 16 mice treated with sunscreens P531, two of 16 mice treated
with P532 plus UVB, two of 13 surviving mice treated with
sunscreen P533 plus UVB, and two of 15 surviving mice treated
with sunscreen P534 plus UVB developed skin tumors.
DISCUSSION
In this study, we evaluated the effectiveness of sunscreens in
protecting against UV-induced p53 mutations and skin cancer
development in C3H mice using a solar simulator as a source of
UV radiation because the proportion of UVB and UVA wavelengths
emitted by the solar simulator more closely approximates that found
in natural sunlight. Therefore, information obtained on induction
as well as prevention of skin cancer in experimental animals by
solar simulators can be more easily extrapolated to human skin
cancers induced by natural sunlight than studies employing other
artificial sunlamps.
Analogous to Kodacel-filtered FS40 sunlamps (Ananthaswamy
et al, 1997), UV radiation from a solar simulator also induced p53
mutations well before the development of skin cancer. In addition,
all four different sunscreen preparations with SPF 15–22 protected
mice against UV-induced p53 mutations. More importantly, 100%
of mice treated with UV alone or vehicle plus UV developed one
or more skin tumors after exposure to 1000 kJ UVB radiation per
m2, whereas only 8% of surviving mice (one of 13) treated with
sunscreens P533 plus UV and none of the mice in the other
sunscreen treated groups (none of 47) developed skin tumors when
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exposed to 1000 kJ UVB per m2. It is interesting to note that even
after 70 wk of UV treatment (cumulative UVB dose of 1500 kJ
per m2), all the sunscreens used in this study afforded significant
(85%) protection against tumor development in that only 19% of
mice treated with sunscreen P531 (three of 16; p 5 0.04, Chi-
square test versus UV only), 13% of surviving mice treated with
sunscreens P532 and P534 (two of 16 and two of 15; p 5 0.04
and.02, respectively) and 15% of the surviving mice treated with
sunscreen P533 (two of 13; p 5 0.04) developed skin tumors.
Based on these results, we can conclude that the sunscreens used
in this study were, at the very least, quite effective in reducing the
tumor incidence and delaying the onset of skin cancer.
Even though sunscreen formulations P531 and P532 contained
only UVB absorbers, they were as effective as P533 and P534
sunscreens, which contained both UVB and UVA absorbers, in
inhibiting UV-induced p53 mutations as well as skin cancer
development. These results suggest that under the experimental
conditions employed, blocking out UVA radiation with sunscreens
containing UVA absorbers do not provide increased photoprotec-
tion against p53 mutations or skin cancer development above that
provided by sunscreen formulations containing only UVB absorbers.
It is difficult, however, to estimate the added protective effect of
UVA sunscreens because of the small differences (small numbers of
animals affected) between the sunscreen-treated groups. Nonethe-
less, these results imply that the mutagenic and carcinogenic effects
of solar simulator radiation is mainly caused by UVB and not UVA
wavelengths. Although we have not looked for UVA-induced p53
mutations in mouse skin irradiated with the solar simulator, it is
unlikely that such mutations play a part in UV skin carcinogenesis
because UVA-type mutations (G→T transversions) (Drobetsky et al,
1995) in the p53 gene are seldom present in human or mouse UV-
induced skin cancers. In addition, studies by van Kranen et al
(1997) have shown that even the mouse skin tumors induced by
massive doses of UVA radiation do not contain G→T transversions
in the p53 gene.
In summary, our studies indicate that sunscreens used in this
study reduce both the induction of p53 mutations as well as
the development of skin tumors, reinforcing the important part
sunscreens can play in the prevention of nonmelanoma skin cancer.
This implies that p53 mutations can serve as an early biologic end-
point of photoprotection against an important initiating event in
UV carcinogenesis. We suggest that it is important to develop
additional biologic end-points that measure promotional events in
the multistep process of photocarcinogenesis to assess fully the role
of sunscreens in protecting against skin cancer induction.
We thank W. Thornton for expert technical assistance and H. Schaefer (L’Oreal),
W. Schwarz (BASF), M. Kayser (BASF), R. Schwarzenbach (F. Hoffmann-La
Roche), R. Goralczyk (F. Hoffmann-La Roche), H. Driller (Merck), and I.
Hoefgen-Mueller (Merck) for providing sunscreen compunds, expert advice and
comments on the manuscript. This study was supported by a sponsored research
agreement from the Photoprotection Assessment Group; M.L.K. is a paid consultant
of one of the members of this group. The animal facilities at the M. D. Anderson
Cancer Center are supported in part by core grant no. CA 16672 from the National
Cancer Institute.
REFERENCES
Ananthaswamy HN, Loughlin SM, Cox P, Evans RL, Ullrich SE, Kripke ML:
Sunlight and skin cancer: Inhibition of p53 mutations in UV-irradiated mouse
skin by sunscreens. Nature Med 3:510–514, 1997
Ananthaswamy HN, Fourtanier A, Evans RL, Tison S, Medaisko C, Ullrich SE,
Kripke ML: p53 mutations in hairless skh-hr1 mouse skin tumors induced by
a solar simulator. Photochem Photobiol 67:227–232, 1998
Berg RJW, van Kranen HJ, Rebel HG, et al: Early p53 alterations in mouse skin
carcinogenesis by UVB radiation. Immunohistochemical detection of mutant
p53 protein in clusters of preneoplastic epidermal cells. Proc Natl Acad Sci USA
93:274–278, 1996
Brash DE, Ziegler A, Jonason AS, Simon JA, Kunala S, Leffell DJ: Sunlight and
sunburn in human skin cancers: p53, apoptosis, and tumor promotion. J Invest
Dermatol Symp Proc 1:136–142, 1996
Bykov VJ, Marcusson JA, Hemminki K: Ultraviolet B-induced DNA damage in
human skin and its modulation by a sunscreen. Cancer Res 58:2961–2964, 1998
Diffey BL, Robson M: A new substrate to measure sunscreen protection factors
throughout the ultraviolet spectrum. J Soc Cosmet Chem 40:127–133, 1989
Drobetsky EA, Turcotte J, Chateauneuf A: A role for ultraviolet A in solar
mutagenesis. Proc Natl Acad Sci USA 92:2350–2354, 1995
Dumaz N, van Kranen HJ, de Vries A, et al: The role of UVB radiation in skin
carcinogenesis through the analysis of p53 gene mutations in squamous cell
carcinomas of hairless mice. Carcinogenesis 18:897–904, 1997
El-Deiry WS, Tokino T, Waldman T, et al: Topological control of p21WAF1/CIP1
expression in normal and neoplastic tissues. Cancer Res 55:2910–2919, 1995
Flindt-Hansen H, Thune P, Larsen TE: The inhibiting effect of PABA on
photocarcinogenesis. Arch Dermatol Res 282:38–41, 1990
Forbes PD, Davies RE, Sambuco CP, Urbach F: Inhibition of ultraviolet radiation-
induced skin tumors in hairless mice by topical application of the sunscreen
2-ethylhexyl-, p-methoxycinnamate. J Toxicol Cutaneous Ocul Toxicol 8:209–
226, 1989
Fourtanier A: Mexoryl® SX protects against solar-simulated UVR-induced
photocarcinogenesis. Photochem Photobiol 64:688–693, 1996
Fourtanier A, Labat-Robert J, Kern P, Berrebi C, Gracia AM, Boyer B: In vivo
evaluation of photoprotection against chronic ultraviolet-A irradiation by a
new sunscreen Mexoryl® SX. Photochem Photobiol 55:549–560, 1992
Freeman SE, Ley RD, Ley KD: Sunscreen protection against UV-induced pyrimidine
dimers in DNA of human skin in situ. Photodermatology 5:243–247, 1988
Gasparro FP, Mitchnick M, Nash JF: A review of sunscreen safety and efficacy.
Photochem Photobiol 68:243–256, 1998
Gilchrest BA: Actinic injury. Annu Rev Med 41:199–210, 1990
Jonason AS, Kunala S, Price GJ, et al: Frequent clones of p53-mutated keratinocytes
in normal human skin. Proc Natl Acad Sci USA 93:14025–14029, 1996
Kanjilal S, Pierceall WE, Cummings KK, Kripke ML, Ananthaswamy HN: High
frequency of p53 mutations in ultraviolet radiation-induced murine skin
tumors: Evidence for strand bias and tumor heterogeneity. Cancer Res 53:2961–
2964, 1993
Kanjilal S, Strom S, Clayman G, et al: p53 mutations in nonmelanoma skin cancer
of the head and neck: Molecular evidence for field cancerization. Cancer Res
55:3604–3609, 1995
Kligman LH, Kligman AM: The nature of photoaging: Its prevention and repair.
Photodermatol 3:215–227, 1986
Kligman LH, Akin FJ, Kligman AM: Sunscreens prevent ultraviolet
photocarcinogenesis. J Am Acad Dermatol 3:30–35, 1980
Kligman LH, Akin FJ, Kligman AM: Prevention of ultraviolet damage to the dermis
of hairless mice by sunscreens. J Invest Dermatol 78:181–189, 1982
Kondoh M, Ueda M, Nakagawa K, Ichihashi M: Siblings with xeroderma
pigmentosum complementation group A with different skin cancer
development: importance of sun protection at an early age. J Am Acad Dermatol
31:993–996, 1994
van Kranen JJ, de Laat A, van de Ven J, et al: Low incidence of p53 mutations in
UVA (365-nm)-induced skin tumors in hairless mice. Cancer Res 57:1238–
1240, 1997
Kress S, Sutter C, Strickland PT, Mukhtar H, Schweizer J, Schwartz M: Carcinogen-
specific mutational pattern in the p53 gene in ultraviolet B radiation-induced
squamous cell carcinomas of mouse skin. Cancer Res 52:6400–6403, 1992
Kripke ML: Immunological effects of ultraviolet radiation. J Dermatol 18:429–
433, 1991
Ley RD, Fourtanier A: Sunscreen protection against ultraviolet radiation-induced
pyrimidine dimers in mouse epidermal DNA. Photochem Photobiol 65:1007–
1011, 1997
Nakazawa H, English D, Randell PL, Nakazawa K, Martel N, Armstrong BK,
Yamasaki H: UV and skin cancer: Specific p53 gene mutation in normal skin
as a biologically relevant exposure measurement. Proc Natl Acad Sci USA
91:360–364, 1994
Nataraj AJ, Trent JT, Ananthaswamy HN: p53 gene mutations and
photocarcinogenesis. Photochem Photobiol 62:218–230, 1995
Naylor MF, Boyd A, Smith DW, Cameron GS, Hubbard D, Neldner KH: High
sun protection factor sunscreens in the suppression of actinic neoplasia. Arch
Dermatol 131:170–175, 1995
Ouhtit A, Ueda M, Nakazawa H, Ichihashi M, Dumaz N, Sarasin S, Yamasaki H:
Quantitative detection of ultraviolet-specific p53 mutations in normal skin
from Japanese patients. Cancer Epidemiol Biomar Preven 6:433–438, 1997
Ouhtit A, Nakazawa H, Armstrong BK, Kricker A, Tan E, Yamasaki H, English
DR: UV-radiation-specific p53 mutation frequency in normal skin as a
predictor of risk of basal cell carcinoma. J Natl Cancer Inst 90:523–531, 1998
Parrish JA, Jaenicke KF, Anderson RR: Erythema and melanogenesis action spectrum
of normal human skin. Photochem Photobiol 36:187–191, 1982
Ponten F, Berne B, Ren ZP, Nister M, Ponten J: Ultraviolet light induces expression
of p53 and p21 in human skin: effect of sunscreen and constitutive p21
expression in skin appendages. J Invest Dermatol 105:402–406, 1995
van Praag MCG, Roza L, Boom BW, Out-Luijting C, Bergen Henegouwen JBA,
Vermeer BJ, Mommaas AM: Determination of the protective efficacy of a
topical sunscreen against UVB-induced DNA damage in human epidermis. J
Photochem Photobiol B Biol 19:129–134, 1993
Ren ZP, Hedrum A, Ponten F, et al: Human epidermal cancer and accompanying
precursors have identical p53 mutations different from p53 mutations in
adjacent areas of clonally expanded non-neoplastic keratinocytes. Oncogene
12:765–773, 1996
Stern RS, Weinstein MC, Baker SG: Risk reduction of nonmelanoma skin cancer
with childhood sunscreen use. Arch Dermatol 122:537–545, 1986
768 ANANTHASWAMY ET AL THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
Thompson SC, Jolley D, Marks R: Reduction of solar keratoses by regular sunscreen
use. N Engl J Med 329:1147–1151, 1993
Ullrich SE, Kim T-H, Ananthaswamy HN, Kripke ML: Sunscreen effects on UV-
induced immune suppression. J Invest Dermatol Symp, in press, 1999
Urano Y, Asano T, Yoshimoto K, et al: Frequent p53 accumulation in the chronically
sun-exposed epidermis and clonal expansion of p53 mutant cells in the
epidermis adjacent to basal cell carcinoma. J Invest Dermatol 104:928–932, 1995
Urbach F: The Biologic Effects of Ultraviolet Radiation. Pergamon Press, New York, 1969
Wolf P, Cox P, Yarosh DB, Kripke ML: Sunscreens and T4N5 liposomes differ in
their ability to protect against ultraviolet-induced sunburn cell formation,
alterations of dendritic epidermal cells, and local suppression of contact
hypersensitivity. J Invest Dermatol 104:287–292, 1995
Wulf HC, Poulsen T, Brodthagen H, Hon-Jenson K: Sunscreens for delay of
ultraviolet induction of skin tumors. J Am Acad Dermatol 7:194–202, 1982
Young AR: Cumulative effects of ultraviolet radiation on the skin: Cancer and
photoaging. Semin Dermatol 9:25–31, 1990
Ziegler A, Jonason AS, Lefell DJ, et al: Sunburn and p53 in the onset of skin cancer.
Nature 372:773–776, 1994
